Snoring & sleep apnea statistics, 2026

Snoring is the noisy end of a spectrum. At one extreme, occasional benign vibration. At the other, airway collapse severe enough to wake you dozens of times an hour without you remembering it. The numbers below come from population surveys, peer-reviewed meta-analyses, and society guidelines.

• 936 million adults aged 30–69 worldwide have OSA, with 425 million in the moderate-to-severe range (Benjafield, Lancet 2019).
• US prevalence sits between 30 million (AMA estimate) and newer high-end estimates of up to 85.6 million US adults across a 24–33% prevalence range (Sleep 2025 supplement).
• Projections published in 2025 suggest 76.6 million US adults aged 30–69 will have OSA by 2050 (Lancet, 2025).
• Snoring is consistently more common in men: roughly 40% of men report snoring vs 20–24% of women. The female-to-male gap narrows after menopause, and the absolute number of women who snore globally is still around 840 million.
• In adults 65+, a Michigan Medicine study found 56% were at high risk for OSA on validated screening (JAGS via AASM Foundation).

The gap between people who likely have OSA and people who have been formally tested is the single most striking number in sleep medicine. It has not closed meaningfully despite two decades of awareness campaigns.

• More than 80% of US adults with moderate-to-severe OSA remain undiagnosed (public health burden review, 2022).
• Only 19% of US adults report ever having had a sleep evaluation, and only 13% have been formally diagnosed with sleep apnea (National Sleep Foundation, 2025).
• Sleep medicine researchers estimate around 68.5 million US adults with OSA are still undiagnosed (Sleep 2025 supplement, prevalence and unmet need).
• Even in older adults — the group most likely to have OSA — screening rates in primary care remain low. Implementation studies of the STOP-BANG questionnaire consistently show that standardising the eight-question screen meaningfully increases referral rates (STOP-BANG performance review, PMC 7941199).

Practical implication: if you snore loudly, wake unrefreshed, or have been told you stop breathing in your sleep, you are statistically more likely to be in the undiagnosed bucket than the diagnosed one. The STOP-BANG screen takes a minute and tells you whether to ask a clinician about a sleep study.

CPAP is the gold-standard medical treatment for OSA, and it works when people use it. The problem is that a large share of people don't, and the rate has been remarkably stable for two decades.

• 43% long-term CPAP adherence in CMS data covering 2000–2016, with "no clinically significant improvement" over 20 years (Rotenberg et al., 2016; age and sex disparities review, PMC 7803941).
• Newer cohort data using the ≥4 hours/night threshold shows roughly 38% non-compliance (MDPI 2024 review).
• Non-adherence is significantly associated with higher 30-day hospital readmission rates (AASM 2024). The cost of a treatment failing isn't just the patient — it propagates into downstream healthcare utilisation.

The takeaway isn't that CPAP is bad. It's that adherence is the rate-limiting step, and the treatment ecosystem now needs lower-friction options that fit into the lives people actually live.

OSA prevalence and treatment access vary sharply by race and ethnicity in the US, and the gap is wider than most clinicians realise. The differences come from a mix of body-composition risk factors, craniofacial structure, social determinants, and access to specialty sleep care.

• OSA prevalence is meaningfully higher among African Americans, Native Americans, and Hispanics compared with non-Hispanic Whites — partly attributable to higher obesity rates and craniofacial structural patterns (PMC 4602395).
• Among adults reporting an OSA diagnosis, Hispanic patients had 50% higher odds of being untreated compared with non-Hispanic Whites (AOR 1.50, 95% CI [1.02, 2.21]) (Sleep 2025 supplement).
• In paediatric data, Hispanic ethnicity was associated with a 28.4% increase in obstructive apnea-hypopnea index, with a more pronounced effect in males (PMC 11446116).
• A 2024 review concluded sleep apnea is "underdiagnosed and undertreated among ethnic minorities," with social determinants, geography, and access to specialty sleep care compounding biological risk (MDPI / Int J Environ Res Public Health).

Most people overestimate or underestimate their own snoring depending on who's complaining. The published acoustic data gives reasonable benchmarks.

• Mild snoring measures around 40–50 dB — the level of a normal conversation. Moderate snoring 50–60 dB. Severe and chronic snoring runs 60–90 dB and the loudest documented cases push past 110 dB, comparable to a chainsaw or motorcycle (Hoffstein, Snoring Intensity & OSA Severity).
• On average, men snore louder than women: mean intensity around 54.1 dB SPL vs 47.4 dB SPL in the same lab conditions (Snoring sound parameters study, 2023).
• Snoring intensity correlates with OSA severity — louder, more consistent snoring tends to be associated with higher AHI — but no single decibel threshold reliably predicts apnea (PMC 2952752). You can't diagnose apnea by the sound alone, but persistent loud snoring is one of the strongest single signals to investigate.

OSA in women looks different to OSA in men, and a lot of sleep medicine is calibrated to the male presentation. Women are diagnosed later, with worse symptoms, and the gap widens around menopause.

• OSA prevalence in women rises sharply after menopause and the male-to-female ratio in diagnosed cases narrows considerably in postmenopausal years (Eval of OSA in primary care, PMC 8740168).
• Women with OSA more often present with insomnia, fatigue, mood symptoms, and morning headaches rather than the textbook loud snoring + witnessed apnea picture — which causes primary-care screening tools to miss them (ScienceDirect, OSAS in women: forgotten gender).
• Anatomical and hormonal differences matter: pharyngeal length, upper-airway cross-sectional area, fat distribution, and progesterone-mediated upper-airway tone all shift across the female lifespan (Clinical synthesis, Apria; Journal of Sleep Medicine).
• Approximately 840 million women globally are habitual snorers, but the conversation around snoring is still framed primarily around men. The female-specific data lags by roughly a decade in most published research.

If you've been told "you don't fit the typical picture" but you wake unrefreshed, snore some nights, or notice mood and energy declining year over year, the underdiagnosis literature is worth taking seriously. The sleep apnea assessment quiz and Epworth sleepiness scale are good starting points for a primary-care conversation.

Pediatric snoring is treated less seriously than it should be. A child who snores nightly isn't "just a noisy sleeper" — they're flagged by every major paediatric society for a workup.

• Pediatric OSA prevalence runs around 1–5% of children, with sleep-disordered breathing in a broader sense affecting up to 9.5% of the pediatric population (PMC 8470037).
• The American Academy of Pediatrics recommends snoring screening at routine well-child visits and a formal diagnostic workup when snoring is paired with daytime symptoms (AAP clinical practice guideline).
• Pediatric sleep-disordered breathing has been linked to attention and behaviour patterns sometimes mistaken for ADHD. Untreated SDB is a known confounder in childhood neurobehavioural assessment (SDB & ADHD review, PMC 8645617; SRBD and ADHD, 2025).
• Maxillary expansion in growing children consistently increases nasal cavity volume and upper airway dimensions, with measurable improvements in nasal respiration (systematic review, 2025).
• Myofunctional therapy reduces AHI by roughly 62% in children across the Camacho meta, and around 43% in newer paediatric cohorts (ScienceDirect 2020).

OSA isn't a sleep-only problem. The American Heart Association's 2021 scientific statement is explicit: OSA is independently associated with a cluster of cardiovascular conditions, with prevalence in cardiac patient populations far above the general baseline.

• OSA prevalence runs 40–80% in patients with hypertension, heart failure, coronary artery disease, pulmonary hypertension, atrial fibrillation, and stroke (AHA 2021 Scientific Statement).
• Patients with both atrial fibrillation and OSA were 3.6× more likely to suffer a first-time stroke than patients with AF alone (Int J Cardiol).
• OSA accelerates the silent-AF burden in stroke patients (Sleep Medicine, 2023), which has direct implications for how cardiologists work up newly diagnosed AF cases.

The cognitive-aging research on OSA has moved fast in the past five years. The signal isn't just "tired people make more mistakes" — there are vascular and hypoxic mechanisms that look like a plausible contributor to long-term brain change, especially in older women.

• A meta-analysis of nine observational studies suggested OSA increases the risk of cognitive decline and dementia in older adults, with effect sizes large enough that researchers are now studying whether treating OSA can change Alzheimer's trajectories (Cognitive Vitality / ADDF).
• In a prospective longitudinal study, 105 elderly women with OSA had a higher risk of developing MCI or dementia compared with women without OSA (PMC 6542637).
• A 2025 UCI study links REM-sleep OSA to small-vessel brain damage and memory loss in older adults, framing chronic intermittent hypoxia as the mechanistic link (UC Irvine, 2025).
• Michigan Medicine: OSA "contributes to dementia in older adults, particularly women." The mechanism is thought to involve hypoxia-driven vascular damage, sleep-architecture disruption, and reduced glymphatic clearance during sleep (Michigan Medicine).

The dollar figure on undiagnosed and untreated OSA is large enough that it shows up in macro-economic studies the same way diabetes does. The AASM-cited numbers are widely used in policy briefings.

• Estimated total annual US economic burden of untreated OSA: $202.9 billion (ResMed Sleep Institute synthesis).
• Of that figure, roughly $86.9B is lost workplace productivity, $26.2B is motor vehicle accident cost, and $6.5B is workplace accidents (AASM 2016 economic burden brief).
• A systematic review across 15 countries put the annual cost per OSA patient in the US at roughly $28,267 — by far the highest in the dataset (Sleep Medicine Reviews).

Sleep apnea is overrepresented in commercial-driver crash data, and drowsy-driving fatalities understate the problem because near-misses don't appear in official statistics.

• NHTSA estimates around 91,000 police-reported drowsy driving crashes per year, with ~50,000 injuries and ~684–800 deaths (NHTSA).
• Drivers averaging 4–5 hours sleep have a 5.4× crash rate compared with 7+ hour sleepers (NHTSA / AAA Foundation).
• Drivers with untreated OSA are roughly 7× more likely to be in a motor vehicle accident (FMCSA evaluation).
• In a 593-person survey of long-distance truck drivers, 47.1% had fallen asleep at the wheel at least once; 25.4% in the past year. Between 7% and 20% of large truck crashes are attributable to drowsy/fatigued driving (Burks et al., 2016).

Most snorers don't get evaluated because of their own discomfort. They get evaluated because the person sleeping next to them runs out of patience. The bed-partner side of this is its own data set.

• 29% of US adults say they have opted for a "sleep divorce" — sleeping in a separate bed or room — to accommodate a partner (AASM 2024 survey).
• ResMed's 2025 Global Sleep Survey of 30,000 people reports 80% of partnered adults say a partner disrupts their sleep, with snoring or loud breathing the #1 cause at 36%.
• Female bed partners of male snorers show measurably reduced sleep quality and increased sleep fragmentation, with a non-trivial subset of those women turning out to have unrecognised snoring themselves (European Respiratory Journal).

We covered this trend in more depth in the long-form article on sleep divorce and snoring, including specialist commentary and a five-step protocol for couples.

Five primary categories of treatment, each with different evidence, adherence, and cost profiles. These are the AHI-reduction figures and adherence proxies we cross-referenced.

• CPAP / PAP therapy: 50–80% AHI reduction when used nightly. Long-term adherence ~43% (CMS data, flat for two decades).
• Oral appliance therapy (MAD): 50–60% AHI reduction in moderate cases. Recommended by AASM/AADSM joint guideline for adults intolerant of CPAP or with primary snoring (clinical guideline).
• Myofunctional therapy: ~50% AHI reduction in adults, ~62% in children across the Camacho meta-analysis; effect persists when delivered via guided apps (smartphone-delivery RCT, PMC 6340784).
• Hypoglossal nerve stimulation (Inspire): ~68% AHI reduction at 12 months (29.3 → 9.0 events/hr); surgical success 72.4% at 12 months and 75% at 60 months (HGNS long-term outcomes).
• Pharmacotherapy (Zepbound / tirzepatide): FDA-approved December 2024 as the first prescription drug for OSA in adults with obesity. AHI improvement linked to body-weight reduction (FDA approval).
• Lifestyle + weight loss: An interdisciplinary 8-week program significantly reduced OSA severity in a 2022 RCT (PMC 9034401). Free, effective, and chronically underused.

A snapshot for journalists, clinicians, and patients trying to compare options. AHI-reduction figures are pulled from the studies cited above; adherence numbers are best-available published estimates. Cost ranges are typical US 2025–26 figures before insurance.

Sources for AHI and adherence figures are linked in the treatment landscape section above. Cost ranges synthesise typical US 2025–26 figures from Inspire, GoodRx, and dental sleep medicine practice surveys.

Cost is part of why adherence numbers look the way they do. None of these figures are static — insurance benefits, durable medical equipment policies, and state-level coverage all shift the out-of-pocket reality — but the spread below is the realistic range US patients see in 2025–26.

• Sleep study (polysomnography): in-lab studies typically bill $1,000–$3,000+ before insurance; home sleep apnea tests usually $150–$500. Coverage varies but most commercial plans cover medically indicated studies after a primary-care referral.
• CPAP equipment: typical machine + supplies run roughly $500–$1,000 initial cost; insurance commonly covers around 80% on a rental-to-own basis for adherent users (Reimels Dentistry coverage synthesis). CMS adherence reporting periods directly affect whether insurance keeps paying.
• Oral appliance therapy: custom mandibular advancement devices typically $1,800–$3,000 with variable insurance coverage; many medical plans require documented CPAP intolerance before covering them.
• Inspire (hypoglossal nerve stimulation): covered by Medicare and many commercial plans for eligible patients; out-of-pocket costs without insurance run into five figures (Inspire cost guide; Medicare coverage rules).
• Sleep apnea surgery: roughly $6,400–$10,000 on average per GoodRx, with wide variation by procedure type and geography (GoodRx).
• Myofunctional therapy / exercise app: in-person myofunctional therapy programs typically $1,500–$4,000 for a full course; app-delivered programs sit in the single-digit-to-tens-of-dollars-per-month range, which is part of why adherence-vulnerable patients increasingly find their way to them.

Two FDA actions, six months apart, quietly rewired the OSA funnel. For the first time the entry point to a sleep-apnea workup can be a smartwatch notification, and the treatment menu now includes a pharmaceutical with real RCT data behind it.

• September 2024: FDA cleared the Apple Watch Sleep Apnea Notification Feature, available on Series 9, Series 10, and Ultra 2. Apple's algorithm analyses Breathing Disturbances over 30-day windows (FDA 510(k) summary; Apple white paper).
• December 2024: FDA approved Zepbound (tirzepatide) for adults with moderate-to-severe OSA and obesity, becoming the first prescription drug for OSA (Eli Lilly press).
• Mouth-taping emerged as a TikTok-driven nighttime ritual in the same window. Two small studies have reported snoring and AHI improvements with mouth tape (sometimes paired with a mandibular advancement device); larger reviews flag potential asphyxiation risk in patients with undiagnosed nasal obstruction and recommend it should not replace medical evaluation for suspected OSA (PMC 12094774; PLOS One systematic review).
• The two changes share a structural implication: the OSA pathway no longer routes everyone through "CPAP or nothing." It now branches into screening at the wrist, exercise programs, oral devices, pharmacotherapy, and surgery. The follow-on question is whether adherence rates improve when patients can pick the treatment that fits their life.